Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE-PVI: Colchicine after Pulmonary Vein Isolation
NCT04160117Phase 3Completed
- Sponsor
- Population Health Research Institute
- Start
- Jan 2020
- Primary completion
- May 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of colchicine in Atrial fibrillation (AFib) (2 arms), sponsored by Population Health Research Institute. Primary endpoints: Average monthly enrollment rate, Compliance with study treatment at 10 days and 1 more. Started Jan 2020; status: completed.
02
Drugs
colchicine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04160117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04160117.